US 12,116,399 B2
Von Willebrand factor proteins for treating bleeding disorders
Philip Zakas, Cambridge, MA (US); David Lillicrap, Kingston (CA); Christopher Doering, Atlanta, GA (US); Eric Gaucher, Atlanta, GA (US); Caelan Radford, Seattle, WA (US); and Harold Trent Spencer, Atlanta, GA (US)
Assigned to Queen's University at Kingston, Kingston (CA); Kingston Health Sciences Centre, Kingston (CA); Emory University, Atlanta, GA (US); and Georgia Tech Research Corporation, Atlanta, GA (US)
Appl. No. 16/760,206
Filed by QUEEN'S UNIVERSITY AT KINGSTON, Kingston (CA); KINGSTON HEALTH SCIENCES CENTRE, Kingston (CA); EMORY UNIVERSITY, Atlanta, GA (US); and GEORGIA TECH RESEARCH CORPORATION, Atlanta, GA (US)
PCT Filed Nov. 1, 2018, PCT No. PCT/CA2018/051389
§ 371(c)(1), (2) Date Apr. 29, 2020,
PCT Pub. No. WO2019/084691, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/580,133, filed on Nov. 1, 2017.
Prior Publication US 2020/0347116 A1, Nov. 5, 2020
Int. Cl. C07K 14/745 (2006.01); A61K 38/36 (2006.01); A61P 7/04 (2006.01); C07K 14/755 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/755 (2013.01) [A61P 7/04 (2018.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C12N 2740/10043 (2013.01)] 14 Claims
 
1. A recombinant non-naturally occurring von Willebrand Factor (VWF) protein comprising the amino acid sequence of SEQ ID NO: 6 (An101-VWF), SEQ ID NO: 8 (An84-VWF), SEQ ID NO: 10 (An63-VWF), SEQ ID NO: 7 (An88-VWF) or SEQ ID NO: 9 (An70-VWF).